Clinical trials: Chidamide
Multiple Myeloma
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients
- Trial name
- NCT03605056
- Testing
- chidamide, lenalidomide, dexamethasone
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peng Liu
Chronic HIV Infections
Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART).
- Trial name
- CHARTER (NCT02513901)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Tang-Du Hospital
Colorectal Cancer
Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced…
- Trial name
- NCT06858956
- Testing
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
- Volunteers
- 200 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Acute Lymphoblastic Leukemia, Philadelphia Chromosome
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
ABC study is a phase 2, single-arm, open-label study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in patients with newly diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
- Conditions
- Acute Lymphoblastic Leukemia, Philadelphia Chromosome, Philadelphia-Positive ALL, Adult ALL
- Trial name
- ABC (NCT06220487)
- Testing
- Prednisone, Olverembatinib, Blinatumomab, Chidamide
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diffuse Large B-Cell Lymphoma
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
To evaluate the efficacy and safety of CAGM regimen in R/R DLBCL patients and to provide a safe and more effective approach for R/R DLBCL patients.
- Trial name
- NCT05823701
- Testing
- Chidamide, Azacitidine, obinutuzumab
- Where
- China
- Volunteers
- 23 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Triple Negative Breast Cancer
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer Patients
The objective of this study is to evaluate the efficacy and safety of a new treatment regimen (Chidamide combined with Zimberelimab) in the treatment of patients with metastatic triple negative breast cancer after the second-line…
- Trial name
- NCT05632848
- Testing
- Chidamide combined with Zimberelimab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Chronic HIV Infections
Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART).
- Trial name
- NCT02902185
- Testing
- ART plus Chidamide
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Hepatocellular Carcinoma (HCC)
Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)
This open-label, phase Ib/II, multicenter study evaluated the safety, tolerability, efficacy, and PK of chidamide in combination with regorafenib in patients with HCC.
- Trial name
- NCT05770882
- Testing
- Chidamide, Regorafenib
- Where
- 5 sites in Taiwan
- Volunteers
- 7 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Neuroblastoma (NB), Neuroblastoma in Children
Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children
This is a Phase II clinical trial investigating the effectiveness and safety of a four-drug combination-Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide-for children with relapsed or refractory neuroblastoma.
- Trial name
- NCT07318831
- Testing
- Chidamide Combined with Dinutuximab Beta, Irinotecan, and Temozolomide
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Peripheral T Cell Lymphoma
A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL).
Objective:This study aims to assess the efficacy and safety of Chidamide as a monotherapy maintenance treatment for patients with newly diagnosed peripheral T-cell lymphoma (PTCL) who have achieved remission or stable disease…
- Trial name
- NCT06550336
- Testing
- Chidamide
- Where
- China
- Volunteers
- 35 people
- Sponsor
- The First Hospital of Jilin University
Diffuse Large B-Cell Lymphoma (DLBCL)
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
Efficacy and safety of chidamide in combination with the R-mini CHOP regimen, followed by chidamide plus CD20 monoclonal antibody as maintenance therapy, in elderly patients with newly diagnosed MYC/BCL2 double-expressor DLBCL.
- Trial name
- NCT07493148
- Testing
- Chidamide, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ou Bai, MD/PHD
HIV/AIDS
Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir
To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART.
- Trial name
- NCT03980691
- Testing
- Chidamide with CAR-T or TCR-T cell therapy
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Guangzhou 8th People's Hospital
Diffuse Large B-cell Lymphoma
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
This is a prospective phase II clinical trial to observe the efficacy and safety of Chidamide combined with VDDT(vinorelbine，liposomal doxorubicin，dexamethasone and thalidomide) in relapsed and refractory patients with diffuse…
- Trial name
- NCT02733380
- Testing
- Chidamide, Vinorelbine, Liposomal Doxorubicin or mitoxantrone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Henan Cancer Hospital
Adult T-cell Leukemia/Lymphoma
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
ETP-ALL like patients have poor outcomes and prognosis, and the optimal therapeutic approaches are poorly characterized. The goal of this clinical trial is to evaluate the efficacy and safety of the venetoclax combined with…
- Trial name
- NCT07159620
- Testing
- VEN (Venetoclax), Azacitidine (AZA), Chidamide
- Where
- China
- Volunteers
- 27 people
- Sponsor
- The First Affiliated Hospital of Soochow University
HR Positive HER2 Negative Advanced Breast Cancer
Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure
To explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR+/ HER2-advanced metastatic breast cancer
- Trial name
- NCT05335473
- Testing
- Eribulin and Tucidinostat
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Henan Cancer Hospital
Peripheral T Cell Lymphoma
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
This is a single arm, prospective trial to evaluate the efficacy and safety of Chidamide in combination with previous chemotherapy in peripheral T cell lymphoma patients who did not achieve complete response after 3 cycles of…
- Trial name
- NCT02753543
- Testing
- Chidamide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Ruijin Hospital
Peripheral T Cell Lymphoma
Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)
This study evaluates the efficacy and safety of Chidamide plus CHOP regimen for de novo PTCL patients.
- Trial name
- CHOP (NCT03268889)
- Testing
- Chidamide
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer
Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of…
- Trial name
- NCT05085626
- Testing
- fluzoparib+chidamide, fluzoparib+camrelizumab
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy
DCHA as Postremission Therapy for AML With t(8;21)
Acute myelocytic leukemia ( AML) is a highly heterogeneous group of malignant hematopathy. Chromosomal translocation with t (8; 21) (q22; q22) , about 10 ~ 15% incidence in AML and 40% incidence in the AML-M2 type of leukemia, is…
- Trial name
- NCT03453255
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese PLA General Hospital